Operating cash flow increased 48% and adjusted free cash flow rose 72% year-over-year. The company achieved core revenue growth of 5.5% along with a 9.5% growth in the Diagnostics segment. The growth in Diagnostics was led by Cepheid, a medical diagnostics company Danaher acquired in 2016
On the downside, the company saw softness in markets like China and the Middle East, which has been impacting its business.
Danaher completed the acquisition of Integrated DNA Technologies Inc. last week, expanding its operations into the genomics consumables space.
For the second quarter of 2018, Danaher expects GAAP EPS to be $0.88 to $0.91 and adjusted EPS to be $1.07 to $1.10.
For the full year of 2018, Danaher expects GAAP EPS of $3.62 to $3.69 and adjusted EPS of $4.38 to $4.45.